- Home
- NAUT vs CDXC Comparison
NAUT vs CDXC Comparison
Compare NAUT & CDXC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NAUT
- CDXC
- Stock Information
- Founded
- NAUT 2016
- CDXC 1999
- Country
- NAUT United States
- CDXC United States
- Employees
- NAUT N/A
- CDXC N/A
- Industry
- NAUT Biotechnology: Laboratory Analytical Instruments
- CDXC Medicinal Chemicals and Botanical Products
- Sector
- NAUT Industrials
- CDXC Health Care
- Exchange
- NAUT Nasdaq
- CDXC Nasdaq
- Market Cap
- NAUT 284.7M
- CDXC 415.5M
- IPO Year
- NAUT N/A
- CDXC N/A
- Fundamental
- Price
- NAUT $1.69
- CDXC $5.48
- Analyst Decision
- NAUT Hold
- CDXC Strong Buy
- Analyst Count
- NAUT 3
- CDXC 2
- Target Price
- NAUT $3.58
- CDXC $8.00
- AVG Volume (30 Days)
- NAUT 162.1K
- CDXC 587.4K
- Earning Date
- NAUT 02-26-2025
- CDXC 10-31-2024
- Dividend Yield
- NAUT N/A
- CDXC N/A
- EPS Growth
- NAUT N/A
- CDXC N/A
- EPS
- NAUT N/A
- CDXC 0.02
- Revenue
- NAUT N/A
- CDXC $91,668,000.00
- Revenue This Year
- NAUT N/A
- CDXC $18.64
- Revenue Next Year
- NAUT N/A
- CDXC $20.72
- P/E Ratio
- NAUT N/A
- CDXC $274.95
- Revenue Growth
- NAUT N/A
- CDXC 9.95
- 52 Week Low
- NAUT $1.61
- CDXC $1.36
- 52 Week High
- NAUT $3.25
- CDXC $7.97
- Technical
- Relative Strength Index (RSI)
- NAUT 31.68
- CDXC 39.30
- Support Level
- NAUT $1.61
- CDXC $5.26
- Resistance Level
- NAUT $1.85
- CDXC $5.56
- Average True Range (ATR)
- NAUT 0.14
- CDXC 0.29
- MACD
- NAUT -0.00
- CDXC -0.09
- Stochastic Oscillator
- NAUT 15.53
- CDXC 18.88
About NAUT Nautilus Biotechnolgy Inc.
Nautilus Biotechnology Inc is a development stage life sciences company creating a platform technology for quantifying and unlocking the complexity of the human proteome. It has built a prototype of a single-molecule instrument, Proteomic Analysis System.
About CDXC ChromaDex Corporation
ChromaDex Corp is a bioscience company dedicated to healthy aging. It is engaged in research on nicotinamide adenine dinucleotide (NAD+), levels of which decline with age. The company is the innovator behind NAD+ precursor nicotinamide riboside (NR), commercialized as the flagship ingredient Niagen. The company has three reportable segments namely Consumer Products, Ingredients segment, and Analytical Reference Standards and Services. The majority of the revenue is earned from the Consumer Products segment.